Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma

To test the potential of immunoreactive BSP, a non-collagenous bone matrix component, as a clinical guide in patients with plasma cell dyscrasias, serum BSP concentrations were measured in 62 patients with newly diagnosed multiple myeloma (MM) followed over a period of 4 years, in 46 patients with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Woitge, H W, Pecherstorfer, M, Horn, E, Keck, A-V, Diel, I J, Bayer, P, Ludwig, H, Ziegler, R, Seibel, M J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363749/
https://www.ncbi.nlm.nih.gov/pubmed/11161399
http://dx.doi.org/10.1054/bjoc.2000.1614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363749/
https://www.ncbi.nlm.nih.gov/pubmed/11161399
http://dx.doi.org/10.1054/bjoc.2000.1614

Ejemplares similares